Global Rank endpoint
Russian translation: см.
| 04:25 Dec 13, 2016 |
| English to Russian translations [PRO] Medical - Medical: Cardiology | |||||||
|---|---|---|---|---|---|---|---|
|
| ||||||
|  Selected response from: Margarita Vidkovskaia Russian Federation Local time: 20:52 | ||||||
Grading comment
| |||||||
| Summary of answers provided | ||||
|---|---|---|---|---|
| 4 +1 | см. |
| ||
| 4 +1 | см. |
|
| Summary of reference entries provided | |||
|---|---|---|---|
| Global Rank Method: Combing Biomarkers and Clinical End Points |
|
| Discussion entries: 2 | |
|---|---|
Answers
33 mins confidence: 
peer agreement (net): +1
peer agreement (net): +1| global rank endpoint см. Explanation: результат (конечная точка клинического исследования), оцениваемый по методу общего (глобального) ранга (рейтинга) One such approach that may be ideal for use in trials of biologics and devices for treatment of CLI is the global rank method, which was initially proposed in 1984 as a means of dealing with composite and repetitive end points. 24 Unlike the traditional time-to-event analysis, global-rank methodology allows consideration of recur- rent events in the final, permits different directionality of the effect of the therapies on the component end points and differentiates severity of events by assigning relative rankings to events. Reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950277/ |
| |||||||||||||||||||||
3 hrs confidence: peer agreement (net): +1
| ||||||||||||||||||||||
27 mins |
| Reference: Global Rank Method: Combing Biomarkers and Clinical End Points Reference information: Global Rank Method: Combing Biomarkers and Clinical End Points Incorporating biomarkers into end points in clinical trials requires a framework for combining both clinical events and continuous data into a unified metric. This is in contrast to the way most end points in phase III clinical trials are framed, most typically as “time-to-event” analyses, for example, time to cardiovascular death or HF hospitalization. Given that phase II studies are, by definition, underpowered to conclusively demonstrate significant differences on clinical end points, alternative approaches are necessary. One such approach is to examine the results across multiple clinical end points while recognizing that none are likely to reach nominal statistical significance and basing decisions on the totality of observed trends across multiple clinical domains. http://circheartfailure.ahajournals.org/content/3/5/643 |
| |
| Login to enter a peer comment (or grade) | ||
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.
KudoZ™ translation help
The KudoZ network provides a framework for translators and others to assist each other with translations or explanations of terms and short phrases.
See also:
Search millions of term translations
Your current localization setting
English
Select a language
Close search